Stockscreener 앱 받기
49.78
15.84%
-9.37
시간 외 거래:
50.65
0.87
+1.75%
전일 마감가:
$59.15
열려 있는:
$57.12
하루 거래량:
74.06M
Relative Volume:
2.45
시가총액:
$10.83B
수익:
$1.78B
순이익/손실:
$164.40M
주가수익비율:
72.14
EPS:
0.69
순현금흐름:
$236.51M
1주 성능:
-7.73%
1개월 성능:
-1.13%
6개월 성능:
+82.81%
1년 성능:
+130.89%
1일 변동 폭
$49.60
$57.45
1주일 범위
$49.60
$65.30
52주 변동 폭
$18.32
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
HIMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
49.78 | 13.37B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
144.06 | 63.49B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.04 | 43.84B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.48 | 40.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.31 | 22.52B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.34 | 19.57B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet - Benzinga
Should the New Menopause Specialty and CEO Share Sale Prompt a Closer Look at HIMS? - simplywall.st
Hims & Hers CEO sells, analyst calls on Planet Fitness & Deere - Yahoo Finance
Hims & Hers stock sinks amid launch of menopause care - The Business Journals
Hims & Hers Stock Nosedives -- CEO Cashes Out $11 Million Stake - Yahoo Finance
Hims & Hers Health (HIMS) Stock Tanks 13% after CEO Discloses Stock Sale - TipRanks
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom - ts2.tech
Why Is Hims & Hers Health Stock Down 12% Today? - MSN
Hims & Hers Health down 11% after CEO Dudum stock sale disclosure - Seeking Alpha
Hims & Hers Health stock falls after Trump promises lower weight loss drug prices - Investing.com
Why Hims & Hers Health Shares Are Sliding Friday - Benzinga
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - sharewise.com
Hims & Hers Health, Inc. (HIMS) Stock forecasts - Yahoo
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Benzinga
Hims & Hers CEO sells stock after menopause expansion announcement - Sherwood News
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - TradingView
Hims & Hers Elevates Technology-Driven Healthcare Accessibility - Yahoo Finance
Hims & Hers (HIMS) Soars 16% as Firm On Track to Book $1 Billion Revenues from Women Segment - MSN
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem - Benzinga
Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade) (NYSE:HIMS) - Seeking Alpha
Hims & Hers Stock Notches Best Day In 3 Months After BofA’s Bullish Call On Menopause Launch: Retail Hails Year’s ‘Best Swing Trade Stock’ - Stocktwits
Hims & Hers Health (HIMS) Stock: Menopause Platform Launch Sparks Rally - parameter.io
What’s The Upside Potential For Hims & Hers Stock? - Trefis
How To Buy HIMS For A 24% Discount, Or Achieve An 82% Annual Return - Barchart.com
Hims & Hers Stock Jumps 9% After Huge Announcement - The Globe and Mail
Trending tickers: TSMC, Salesforce, Hims & Hers Health, Nestlé and Whitbread - Yahoo
Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today - inkl
Why Hims & Hers Stock Blasted 16% Higher on Wednesday - The Globe and Mail
Hims & Hers Stock Soars on New Menopause Care Expansion – What Comes Next? - ts2.tech
Hims & Hers stock climbs after menopause care launch - Rolling Out
Weight-loss drugs shook up the stock market. Menopause treatments could be next. - MarketWatch
Investors Are Buying Hims & Hers Health Stock Following Wednesday's Platform Expansion Announcement - Benzinga
Why Are Hims & Hers Health (HIMS) Shares Soaring Today - The Globe and Mail
Hims & Hers: Telehealth Triumph or Trouble? - StocksToTrade
FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly - MedShadow Foundation
Hims & Hers stock faces competition concerns despite positive BofA view - Investing.com
Hims & Hers Health (HIMS) Expands into Menopause Treatments - GuruFocus
Hims & Hers offers menopause, perimenopause treatments - Seeking Alpha
Hims & Hers Health Brings Menopause, Perimenopause Treatments On Its Platform - Stocktwits
Hims & Hers launches perimenopause and menopause care on platform - Investing.com India
Hims & Hers stock rises after launching menopause treatment services By Investing.com - Investing.com Nigeria
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026 - Hims Investor Relations
Hims & Hers to Offer Treatments for Menopause, Perimenopause - The Wall Street Journal
Hims & Hers stock rises after launching menopause treatment services - Investing.com
Not Your Mother's Menopause: Hers Sets a New Standard of Care for Women - Hims & Hers Newsroom
Promising Healthcare Stocks To ResearchOctober 14th - MarketBeat
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell? - Yahoo Finance
Should Investors Buy UnitedHealth Stock Instead of Hims & Hers Stock? - The Motley Fool
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025 - Hims Investor Relations
Hims & Hers: Why I’m Betting On HIMS Heading To $100 (NYSE:HIMS) - Seeking Alpha
Best Healthcare Stocks To Keep An Eye OnOctober 12th - MarketBeat
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.39%
자본화:
|
볼륨(24시간):